30%–60% of patients with GBM presenting MGMT gene silencing induced by hypermethylation in the promoter region are more likely to benefit from alkylating agent‐based chemotherapy to achieve longer survival times [35, 36]. This evidence concerns the gene MGMT and glioblastoma.